{
    "nctId": "NCT05376644",
    "briefTitle": "Molecular Imaging of HER2 Expression in HER2-positive Breast Cancer Using 99mTc-ADAPT6 vs 99mTc-DARPinG3",
    "officialTitle": "SPECT Imaging of Human Epidermal Growth Factor Receptor 2 (HER2) Using 99mTc-ADAPT6 and 99mTc-DARPinG3 in HER2-positive Breast Cancer Patients Before System (Chemo/Targeted) Therapy.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer Female",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 15,
    "primaryOutcomeMeasure": "99mTc-ADAPT6 uptake (counts)/SUV",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Subject is \\> 18 years of age;\n2. Diagnosis of primary breast cancer with possible lymph node metastases before system (chemo+targeted therapy);\n3. Availability of results from HER2 status previously determined on material from the primary tumor: HER2-positive, defined as a DAKO HercepTest\u2122 score of 3+ or FISH positive;\n4. Sequential injection of 99mTc-ADAPT6 and 99mTc-DARPinG3 in the interval of 3-4 days in each HER2-positive breast cancer patient;\n5. Hematological, liver and renal function test results within the following limits:\n\n   * White blood cell count: \\> 2.0 x 109/L\n   * Hemoglobin: \\> 80 g/L\n   * Platelets: \\> 50.0 x 109/L\n   * ALT, ALP, AST: =\\< 5.0 times Upper Limit of Normal\n   * Bilirubin =\\< 2.0 times Upper Limit of Normal\n   * Serum creatinine: Within Normal Limits\n6. A negative pregnancy test for all patients of childbearing potential. Sexually active women of childbearing potential participating in the study must use a medically acceptable form of contraception for at least 30 days after study termination;\n7. Subject is capable to undergo the diagnostic investigations to be performed in the study;\n8. Informed consent\n\nExclusion Criteria:\n\n1. Second, non-breast malignancy 2. Active current autoimmune disease or history of autoimmune disease 3. Active infection or history of severe infection within the previous 3 months (if clinically relevant at screening) 4. Known HIV positive or chronically active hepatitis B or C 5. Administration of other investigational medicinal product within 30 days of screening 6. Ongoing toxicity \\> grade 2 from previous standard or investigational therapies, according to US National Cancer Institute's\n\n-",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}